Dr. Jordi Monés helps to create guidelines for the treatment of neovascular AMD for EURETINA

Dr. Jordi Monés, MD, PhD, the Director and ophthalmologist specialising in macula, retina and vitreous at the Institut de la Màcula, has contributed to the compiling of “Guidelines for the Treatment of neovascular Age-Related Macular Degeneration” for the European Society of Retina Specialists (EURETINA). The study has been published in the British Journal of Ophthalmology, one of the world’s most prestigious in the field.

This Guideline includes recommendations and advances, such as the identification of the vascular endothelial growth factor as a key element in the development of the disease, and the development of drugs aimed at controlling the secretion of this protein. These have led to a substantial improvement in the prognosis of patients affected by neovascular AMD, enabling the vast majority to recover and maintain the visual function.

Nevertheless, this therapeutic benefit needs to be accompanied by considerable financial investment, medical and legal debates on the use of non-approved drugs that are still unresolved and problems in the care of patients in day-to-day clinical practice.

Ten experts in macula, retina and vitreous from around the world have participated in the study, with Dr. Monés being the only one from Spain. The others include ophthalmologists from Austria, Israel, the United Kingdom, France, the Netherlands and Germany.

EURETINA provides assessment and support to ophthalmologists in the diagnosis and treatment of neovascular AMD so that they can improve patients’ medical care.

You can read the full article in the next link.